



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 023070-087910US  
Client Ref. No.: UC 98-009-2

U.S. Patent and Trademark Office  
Box SEQUENCE  
P.O. Box 2327  
Arlington, VA 22202

On May 28, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Michelle Howell

#518  
180  
RECEIVED  
JUN 06 2002  
TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

ROSE *et al.*

Application No.: 09/832,510

Filed: April 10, 2001

For: ANTIGENIC EPITOPES WITH  
LYM-1 REACTIVITY AND USES  
THEREOF

Examiner: Huff, Sheela Jitendra

Art Unit: 1642

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

U.S. Patent and Trademark Office  
Box SEQUENCE  
P.O. Box 2327  
Arlington, VA 22202

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Action mailed April 26, 2002, Applicants submit that the computer-readable form in the instant application is identical with the Sequence Listing filed in Application No. 09/181,896, filed December 16, 1999. In accordance with 37 C.F.R. § 1.821(e), please use the computer-readable form filed in Application No. 09/181,896 as the computer-readable form for the instant application.

The information in the paper copy of the Sequence Listing enclosed herewith is identical to that which is in the computer readable form, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

**In the Specification:**

Please replace the paragraph beginning at page 2, line 21, with the following:

B<sup>1</sup>

— In one embodiment, the peptide of the invention has a structure wherein R<sub>1</sub> is Gln, Lys, or Arg; R<sub>2</sub> is Arg; R<sub>3</sub> is Arg; R<sub>4</sub> is selected from the group consisting of all amino acids; R<sub>5</sub> is Ala; R<sub>6</sub> and R<sub>7</sub> are members independently selected from the group consisting of all amino acids; R<sub>8</sub> is Thr; R<sub>9</sub> is selected from the group consisting of all amino acids; R<sub>10</sub> is Cys; R<sub>11</sub>, R<sub>12</sub>, R<sub>13</sub>, R<sub>14</sub>, and R<sub>15</sub> are members independently selected from the group consisting of all amino acids; and, R<sub>16</sub> is Val (SEQ ID NO:1). In a preferred embodiment, the immunogenic peptide comprises a structure wherein R<sub>1</sub> is Gln, Lys, or Arg; R<sub>2</sub> is Arg; R<sub>3</sub> is Arg; R<sub>4</sub> is Ala; R<sub>5</sub> is Ala; R<sub>6</sub> is Val; R<sub>7</sub> is Asp; R<sub>8</sub> is Thr; R<sub>9</sub> is Tyr; R<sub>10</sub> is Cys; R<sub>11</sub> is Arg; R<sub>12</sub> is His; R<sub>13</sub> is Asn; R<sub>14</sub> is Tyr; R<sub>15</sub> is Gly, and R<sub>16</sub> is Val (SEQ ID NO:2).

Please replace the paragraph beginning at page 3, line 4, with the following:

B<sup>2</sup>

— The invention also provides a method for detecting a nucleic acid in a biological sample, wherein the nucleic acid encodes a peptide capable of specifically binding to a Lym-1 antibody. The method of the invention comprises contacting the sample with an oligonucleotide primer pair capable of amplifying a subsequence of an